Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory Multiple Myeloma
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a article by Sikander Ailawadhi on X:
“Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.”
Authors: Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver and Paula Rodríguez-Otero
More posts featuringMohamed Benlazar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023